Asset Details
Do you wish to reserve the book?
Attention‐deficit/hyperactivity disorder impacts the development of neuropsychiatric symptoms in Alzheimer’s disease
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Attention‐deficit/hyperactivity disorder impacts the development of neuropsychiatric symptoms in Alzheimer’s disease
Do you wish to request the book?
Attention‐deficit/hyperactivity disorder impacts the development of neuropsychiatric symptoms in Alzheimer’s disease
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Attention‐deficit/hyperactivity disorder impacts the development of neuropsychiatric symptoms in Alzheimer’s disease
2024
Overview
Background Recent studies have shown that patients with attention‐deficit/hyperactivity disorder (ADHD) are more likely to be diagnosed with mild cognitive impairment (MCI) and Alzheimer’s Disease (AD). Increased genetic risk for ADHD, measured with ADHD polygenic risk scores (ADHD‐PRS), was associated with a more severe AD presentation, including worse cognitive function and higher tau pathology. Neuropsychiatric symptoms (NPSs) are common in AD and are hypothesized to occur with disease progression. It is unclear whether ADHD predispose individuals to the development of NPSs. Method We used data from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) to investigate the associations between ADHD‐PRS and the development of NPSs in cognitively impaired (CI, including MCI and AD) subjects who had brain amyloidosis at baseline. NPSs were assessed with the NPI or NPI‐Q and divided into four syndromes: hyperactive (agitation, disinhibition, irritability, and aberrant motor behavior), psychosis (delusions, hallucinations, and night‐time behavior disturbances), apathy (apathy and appetite and eating abnormalities), and affective (depression and anxiety). Additionally, we tested the specificity of our findings by analyzing the association between the genetic risk for depression, bipolar disorder (BD), schizophrenia, and autism spectrum disorder (ASD) with the development of NPSs. Data were represented with Kaplan‐Meier survival curves, and analyses were performed with Cox proportional hazards regression models controlled by age, sex, and ancestry. Result We evaluated data from 852 participants (636 MCI [74.1%], 350 women [40.8%], mean [SD] age of 73.4 [7.3] years). ADHD‐PRS was associated with a higher risk of developing hyperactive (HR 1.41; 95% CI 1.04‐1.89) and apathy (HR 1.34; 95% CI 1.01‐1.77) symptoms, but not psychosis (HR 1.04; 95% CI 0.78‐1.41) or affective (HR 0.97; 95% CI 0.72‐1.32) symptoms. There was no association between the genetic risk for depression, BP, schizophrenia, or ASD with any neuropsychiatric syndrome. Conclusion Findings indicate that a higher genetic risk for ADHD may be a risk factor for the development of hyperactive and apathy symptoms in CI individuals. These effects were specific for ADHD and were not observed for other prevalent psychiatric disorders. Clinically, our results contribute to the literature that highlights the need for tailored assessments for CI individuals with ADHD histories.
Publisher
John Wiley and Sons Inc
Subject
